NVCR - ノボキュア (NovoCure Limited)

NVCRのニュース

   Top Analyst Upgrades and Downgrades: Boston Scientific, CVS, FMC, Lennar, NovoCure, Penn National, Ruth’s, Stitch Fix, Veeco and More  2020/09/17 12:58:15 24/7 Wall street
   The Daily Biotech Pulse: Moderna Inks 2 R&D Deals, BioNTech To Buy Manufacturing Facility, Dyne Therapeutics IPO  2020/09/17 11:59:47 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 16) Arena Pharmaceuticals, Inc. (NASDAQ: ARNA ) (the first subject has been dosed in a Phase 3 trial evaluating etrasimod for the potential treatment of moderately to severely active ulcerative colitis) Beigene Ltd (NASDAQ: BGNE ) BioLife Solutions Inc (NASDAQ: BLFS ) Checkpoint Therapeutics Inc (NASDAQ: CKPT ) Denali Therapeutics Inc (NASDAQ: DNLI ) Dr.Reddy's Laboratories Ltd (NYSE: RDY ) (announced a deal with Russia for 100 million doses of Sputnik-V vaccine against the coronavirus) Fortress Biotech (NASDAQ: FBIO ) Guardant Health Inc (NASDAQ: GH ) Immunovant Inc (NASDAQ: IMVT ) Insmed Incorporated (NASDAQ: INSM ) InVitae Corp (NYSE: NVTA ) Marinus Pharmaceuticals Inc (NASDAQ: MRNS ) Mersana Therapeutics Inc (NASDAQ: MRSN ) Mirati Therapeutics Inc (NASDAQ: MRTX ) Myokardia Inc (NASDAQ: MYOK ) Nevro Corp (NYSE: NVRO ) Novocure Ltd (NASDAQ: NVCR ) Pacific Biosciences of California Inc (NASDAQ: PACB ) Protagonist Therapeutics Inc (NASDAQ: PTGX ) RedHill Biopharma Ltd (NASDAQ: RDHL ) Revance Therapeutics Inc (NASDAQ: RVNC ) SI-Bone Inc (NASDAQ: SIBN ) Silk Road Medical Inc (NASDAQ: SILK ) Turning Point Therapeutics Inc (NASDAQ: TPTX ) Down In The Dumps (Biotech Stocks Hitting 52-week Lows Sept. 16) PainReform Ltd (NASDAQ: PRFX ) Pandion Therapeutics Inc (NASDAQ: PAND ) SILENCE THERAPE/S ADR (NASDAQ: SLN ) Stocks In Focus Moderna Announces 2 R&D Collaborations For Up To $880M Moderna Inc (NASDAQ: MRNA ) and Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX ) announced a three-year strategic research collaboration and licensing agreement aimed at the discovery and development of lipid nanoparticles and mRNAs for the delivery of gene-editing therapies for cystic fibrosis.
   The Daily Biotech Pulse: Moderna Expands Into Switzerland, Tiziana To Spin Off Testing Unit, Metacrine IPO  2020/09/16 12:00:28 Benzinga
Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 15) Avidity Biosciences Inc (NASDAQ: RNA ) Beigene Ltd (NASDAQ: BGNE ) Bicycle Therapeutics PLC (NASDAQ: BCYC ) BioLife Solutions Inc (NASDAQ: BLFS ) Checkpoint Therapeutics Inc (NASDAQ: CKPT ) Denali Therapeutics Inc (NASDAQ: DNLI ) Fate Therapeutics Inc (NASDAQ: FATE ) Guardant Health Inc (NASDAQ: GH ) Horizon Therapeutics PLC (NASDAQ: HZNP ) Immunovant Inc (NASDAQ: IMVT ) InVitae Corp (NYSE: NVTA ) Jounce Therapeutics Inc (NASDAQ: JNCE ) Marinus Pharmaceuticals Inc (NASDAQ: MRNS ) ( announced a positive late-stage readout for ganaxolone) Mirati Therapeutics Inc (NASDAQ: MRTX ) Momenta Pharmaceuticals, Inc. (NASDAQ: MNTA ) Myokardia Inc (NASDAQ: MYOK ) Novocure Ltd (NASDAQ: NVCR ) Outset Medical Inc (NASDAQ: OM ) (more than doubled on its Wall Street debut) Repare Therapeutics Inc (NASDAQ: RPTX ) Revance Therapeutics Inc (NASDAQ: RVNC ) Shockwave Medical Inc (NASDAQ: SWAV ) SI-Bone Inc (NASDAQ: SIBN ) Silk Road Medical Inc (NASDAQ: SILK ) TRACON Pharmaceuticals Inc (NASDAQ: TCON ) Down In The Dumps (Biotech Stocks Hitting 52-week Lows Sept. 15) Histogen Inc (NASDAQ: HSTO ) PainReform Ltd (NASDAQ: PRFX ) Satsuma Pharmaceuticals Inc (NASDAQ: STSA ) SILENCE THERAPE/S ADR (NASDAQ: SLN ) Stocks In Focus Roche Gets Label Expansion For Cancer Screening Test Roche Holdings AG Basel (OTC: RHHBY ) announced FDA approval for the expanded use of CINtec PLUS Cytology, its first triage test based on biomarker technology for women whose cervical cancer screening results are positive for high-risk types of human papillomavirus.
   NovoCure (NVCR): Why this medtech firm matters  2020/09/14 14:37:49 AlphaStreet
Even as COVID-19 is wreaking havoc across the world, cancer continues to kill about 10 million people per year, and the quest for the most effective cure is gaining pace. In fact, the coronavirus pandemic has reportedly accelerated the cancer fatality rate, further stressing the urgent need to scale up oncology research. Thanks to the […]
   Novocure Announces Expansion of Its Executive Leadership Team  2020/08/13 12:30:00 Business Wire
ST. HELIER, Jersey--(BUSINESS WIRE)--Novocure announced an expansion of its Executive Leadership Team, effective Sept. 1, 2020.
   Novocure to Report Second Quarter 2020 Financial Results  2020/07/01 11:30:00 Business Wire
ST. HELIER, Jersey--(BUSINESS WIRE)---- $NVCR #earnings--Novocure will report financial results for the second quarter 2020 on Thursday, July 30, 2020, before the U.S. financial markets open.
   Novocure Announces Launch of MyLink™ to Enable Patient-Guided, Remote Download of Optune® Usage Data  2020/06/02 11:30:00 Business Wire
ST. HELIER, Jersey--(BUSINESS WIRE)--A new tool will enable patients to download their Optune usage data without the need for an in-person visit by a Novocure Device Support Specialist.
   NovoCure (NVCR) Lags Q1 Earnings and Revenue Estimates  2020/04/30 11:30:10 Zacks Investment Research
NovoCure (NVCR) delivered earnings and revenue surprises of -20.00% and -2.19%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
   Novocure Reports First Quarter 2020 Financial Results and Provides Company Update  2020/04/30 10:00:00 Business Wire
ST. HELIER, Jersey--(BUSINESS WIRE)---- $NVCR--Novocure reported financial results for the first quarter of 2020 and provided a company update.
   Novocure Announces Presentation of EF-19 Post-approval Registry Trial Data Studying Optune as a Monotherapy for the Treatment of Recurrent GBM at the American Association for Cancer Research 2020 Virtual Annual Meeting I  2020/04/27 11:30:00 Business Wire
ST. HELIER, Jersey--(BUSINESS WIRE)-- #btsm--Novocure announced that EF-19 post-approval registry trial data will be presented at the AACR 2020 Virtual Annual Meeting I.
   Novocure to Report Second Quarter 2020 Financial Results  2020/07/01 11:30:00 Business Wire
ST. HELIER, Jersey--(BUSINESS WIRE)---- $NVCR #earnings--Novocure will report financial results for the second quarter 2020 on Thursday, July 30, 2020, before the U.S. financial markets open.
   Novocure Announces Launch of MyLink™ to Enable Patient-Guided, Remote Download of Optune® Usage Data  2020/06/02 11:30:00 Business Wire
ST. HELIER, Jersey--(BUSINESS WIRE)--A new tool will enable patients to download their Optune usage data without the need for an in-person visit by a Novocure Device Support Specialist.
   NovoCure (NVCR) Lags Q1 Earnings and Revenue Estimates  2020/04/30 11:30:10 Zacks Investment Research
NovoCure (NVCR) delivered earnings and revenue surprises of -20.00% and -2.19%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
   Novocure Reports First Quarter 2020 Financial Results and Provides Company Update  2020/04/30 10:00:00 Business Wire
ST. HELIER, Jersey--(BUSINESS WIRE)---- $NVCR--Novocure reported financial results for the first quarter of 2020 and provided a company update.
   Novocure Announces Presentation of EF-19 Post-approval Registry Trial Data Studying Optune as a Monotherapy for the Treatment of Recurrent GBM at the American Association for Cancer Research 2020 Virtual Annual Meeting I  2020/04/27 11:30:00 Business Wire
ST. HELIER, Jersey--(BUSINESS WIRE)-- #btsm--Novocure announced that EF-19 post-approval registry trial data will be presented at the AACR 2020 Virtual Annual Meeting I.

calendar